Order Article Reprints

Chae H, Sim SH, Kwon Y, Lee E-G, Han JH, Jung S-Y, Lee S, Kang H-S, Kim Y-J, Kim TH, et al. Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). Cancers. 2024; 16(18):3122. https://doi.org/10.3390/cancers16183122

Chae, Heejung, Sung Hoon Sim, Youngmi Kwon, Eun-Gyeong Lee, Jai Hong Han, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Yeon-Joo Kim, Tae Hyun Kim, and et al. 2024. "Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)" Cancers 16, no. 18: 3122. https://doi.org/10.3390/cancers16183122

Chae, H., Sim, S. H., Kwon, Y., Lee, E.-G., Han, J. H., Jung, S.-Y., Lee, S., Kang, H.-S., Kim, Y.-J., Kim, T. H., & Lee, K. S. (2024). Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). Cancers, 16(18), 3122. https://doi.org/10.3390/cancers16183122